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Objectives: In contrast to other countries, surgery still represents the common invasive treatment for varicose veins
in Germany. However, radiofrequency ablation, e.g. ClosureFast, becomes more and more popular in other
countries due to potential better results and reduced side effects. This treatment option may cause less follow-up
costs and is a more convenient procedure for patients, which could justify an introduction in the statutory benefits
catalogue. Therefore, we aim at calculating the budget impact of a general reimbursement of ClosureFast in
Germany.
Methods: To assess the budget impact of including ClosureFast in the German statutory benefits catalogue, we
developed a multi-cohort Markov model and compared the costs of a “World with ClosureFast” with a “World
without ClosureFast” over a time horizon of five years. To address the uncertainty of input parameters, we
conducted three different types of sensitivity analysis (one-way, scenario, probabilistic).
Results: In the Base Case scenario, the introduction of the ClosureFast system for the treatment of varicose veins
saves costs of about 19.1 Mio. € over a time horizon of five years in Germany. However, the results scatter in the
sensitivity analyses due to limited evidence of some key input parameters.
Conclusions: Results of the budget impact analysis indicate that a general reimbursement of ClosureFast has the
potential to be cost-saving in the German Statutory Health Insurance.
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Primary varicose veins are a degenerative disease of the
wall of the vein in the superficial vein system of the legs.
Various factors (e.g. pregnancy, physical inactivity) affect
the characteristics and severity of varices over a lifetime
[1]. Primary varicose disease has to be differentiated
from less common secondary varicose veins which occur
in the deep vein systems to conditions such as deep vein
thrombosis, pelvic tumors or arteriovenous fistulae [2].
Besides a variety of symptoms of discomfort in the legs
(e.g. itching, heaviness, and aching) [3], varicose veins
can cause more severe complications, for instance* Correspondence: ak@ivbl.uni-hannover.de
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[1,4-6].
The range of reported prevalence data for primary vari-
ces is very wide (2-56% in men and 1-60% in women) due
to variations in the study population, selection criteria,
methods of measurement and disease definition [7-13].
The majority of the literature quotes a study from Callam,
which estimates that the prevalence of visible tortuous
varicose veins in an unselected Western adult population
over the age of 15 years is between 10 and 15% for men
and between 20 and 25% for women [7]. According to the
“Bonner Venenstudie” [13] 12.4% of men and 15.8% of
women had varices without symptoms of chronic vein in-
sufficiency in Germany in 2003. However, the occurrence
of varicose veins varies by age [14]. Studies which estimate
the incidence of primary varices are rare. Nevertheless,is an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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an incidence rate of 13.5 per 1,000 person years (8.5 for
men and 19.2 for women) [15].
Due to the high prevalence the treatment of patients
with varicose veins places a substantial financial burden
on the health care system. For example, the German
Federal Statistical Office estimated health care costs due
to varicose veins (ICD-10: I83 Varicose veins of lower
extremities) at 790 Mio € in 2008 [16]. Hence, analyses
which give a deep insight into costs and benefits of dif-
ferent treatment patterns are important for the German
health care sector in order to identify cost effective treat-
ment options.
Several interventional (e.g. surgery, endovenous thermal
ablations, sclerotherapy) and non-interventional treat-
ments (e.g. compression therapy) of varicose veins exist
and are approved for treatment in Germany. Despite the
growing popularity of new minimally invasive endovenous
treatments for varicose veins in other countries in the past
decade, surgery still represents the standard intervention
in Germany [17], since endovenous thermal ablations
aren’t covered by the general benefits catalogue of the
Statutory Health Insurance (SHI). In contrast to conven-
tional surgery which is often conducted in hospitals with
general or regional anaesthesia, the majority of the minim-
ally invasive techniques are performed as office based pro-
cedures using tumescent local anaesthesia [18].
Recently, a new endovenous thermal ablation named
ClosureFast, which uses radiofrequency techniques to
treat varicose veins, was introduced in the USA. This
improved version of the ClosurePlus device promises re-
duced pain, improved Quality of Life (QoL) and a faster
recovery after treatment in comparison to surgery. Fur-
thermore, comparable effectiveness parameters are
reported [18]. In addition, since ClosureFast is mainly
performed in an outpatient setting, treatment costs may
be reduced by avoiding costly inpatient procedures.
Hence, an inclusion of ClosureFast in the general bene-
fits catalogue of the German SHI should be considered.
To explore the potential financial consequences an eco-
nomic evaluation is necessary.
Besides cost-effectiveness models, budget impact ana-
lyses (BIA) are very important in the German setting. The
purpose of a BIA is to estimate the affordability of a new
health care intervention for health care decision-makers.
The results of these models present the impact of an
innovation on a national annual health care budget [19].
Such an analysis can be helpful to determine if ClosureFast
is an affordable option for the German setting.
Therefore, aim of this study is to examine the budget
impact of a general reimbursement of ClosureFast by the
SHI in Germany.
Before presenting the model structure, input parame-
ters and analysis procedure in the methods section, wewant to give a short overview of the several alternative
treatment options.
Treatment options for varicose veins
Treatment options for varicose veins can be divided into
interventional and non-interventional procedures. Con-
servative, non-interventional treatments such as com-
pression therapies with medical stockings and pantyhose
can be used in every stage of the disease. However, they
neither remove the varice nor hinder its development. In
contrast, non-interventional treatments aim at alleviat-
ing the symptoms [1].
The interventional treatments can be categorized in
sclerotherapy, endovenious thermal therapy and surgery.
Surgical treatment of varicose veins includes high ligation
(crossectomy) and saphenous vein stripping, with or with-
out phlebectomy [20] and has been performed since the
early 20th century. Until recently, high ligation and strip-
ping was the standard treatment for patients with varicose
veins demonstrating improvements in quality of life as
well as reductions in symptoms and reoperation rates
compared with high ligation and phlebectomies only
[21-23]. However, various complications can occur follow-
ing varicose vein surgery. Even though serious complica-
tions such as deep vein thrombosis (1 in 200 patients) or
pulmonary embolism (1 in 600 patients) are rare [24],
minor complications occur frequently. For instance,
reported rates of wound complications including infec-
tion, haematoma and abscess formations vary from 3-10%
[24,25].
Sclerotherapy techniques aim at inducing endothelial
and vein wall damage in a controlled fashion by injecting
toxic liquids or foam in the varice. This results in the ob-
literation of the varicose vein. Sclerotherapy is considered
as the gold standard treatment for leg telangiectasias,
venulectasias, and reticular veins [26]. A disadvantage is
that the treatment of saphenous veins with non-foam
sclerosing agents is associated with high recurrent rates
[27,28]. However, recently, treatment with ultra-sound
guided foam sclerotherapy (UGFS) has shown better re-
sults [29-31].
Minimally invasive endovenous thermal treatments in-
clude endovenous laser ablation (EVLA) and radiofrequency
ablations (RFA). The aim of endovenous thermal abla-
tion is the irreversible obliteration of the varice. For the
EVLA procedure, a thin laser fiber is inserted in the
vein under duplex ultrasound control and heated by laser
energy to cause thermal damage of the vein wall. The
ultrasound guided RFA technique uses radiofrequency en-
ergy which is directed through a small cathether inserted
through a tiny insertion in the vein to heat up the varice
and damage its vein wall. In different randomized trials,
the first-generation RFA device VNUS ClosurePlus and
EVLA showed comparable effectiveness to surgery;
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proved QoL as well as a faster recovery after treatment
[32-42].
In the following section, we will describe the methods
used to explore the potential financial consequences of
an introduction of ClosureFast in the German SHI.
Methods
To assess the budget impact of a “World with
ClosureFast” compared to a “World without ClosureFast”,
a multi-cohort Markov model was developed and pro-
grammed in Microsoft Excel 2007.
The evaluation was conducted from the perspective of
the SHI in Germany. The publication of the ISPOR task
force [43] as well as the manuscript of Nuijten et al. [19]
served as guidelines for the preparation of the BIA. In-
put parameters were derived from a systematic literature
research. In addition, two medical experts in the field of
varicose veins were contacted to provide expert opinions
on present and future market shares of initial and sec-
ondary interventional treatment of varicose veins as well
as resource use.
Model structure
The basic structure of the model was adapted from a re-
cently published cost-effectiveness model of the National
Institute for Health and Clinical Excellence (NICE)
[44,45], illustrated in Figure 1. (For the following de-
scription of the model structure see NICE [44,45].)Figure 1 Structure of the multi cohort Markov model.The time horizon of the model was five years with a
cycle length of one month. Patients enter the model re-
ceiving initial interventional treatment for varicose veins
(state: “1st treatment episode”). Following the comple-
tion of the treatment episode, patients move to the state
“1st varices free episode”, in which they do not require
further treatment. They remain in this state until a vari-
cose vein recurs. Hence, they transit to the state “phys-
ical symptoms of recurrent varicose veins (1)”. A defined
proportion of patients receive a 2nd interventional treat-
ment while the others are treated with conservative care
in form of a compression therapy until the end of the
model’s time horizon (or death). Patients who undergo a
second interventional treatment move on to the state
“2nd varices free episode”, where they remain until they
experience a 2nd clinical recurrence. In case of a 2nd re-
currence, patients only receive conservative care until
the end of the model’s time horizon (or death). Transi-
tion to death is possible from all states of the model.
The annual risk of dying is the same in every health
state. The monthly all-cause death probability was calcu-
lated on the basis of official life tables [46] (Table 1).
To calculate the budget impact, every month, a de-
fined cohort had to enter the model receiving initial
interventional treatment according to given market
shares. Considering the time horizon of five years
(2013–2017), the model included 60 patient cohorts.
However, since recurrence rates play an important role
in the treatment of recurrent varicose veins (see segment
Table 1 Key parameters of the model
• treatment episode consists of interventional treatment for every patient and a top-up treatment (additional treatment in case of complications, i.e.
vein has not been occluded or obliterated) for a defined proportion of patients (i.e. treated vein is not occluded or obliterated)
• maximum of two treatment episodes: initial interventional treatment for all patients and a second interventional treatment for a given proportion
of patients with recurrent varicose veins
• no difference of effectiveness between initial and secondary interventional treatment for each procedure
• top-up treatment is always UGFS and has no influence on recurrence rates
• constant hazard of recurrence
• 6 month delay between onset of clinical recurrence and second treatment episode
• conservative care is given to patients with recurrent varicose veins who do not undergo a second treatment episode as clinical recurrence is not
considered clinically meaningful and to all patients with a second recurrence
Source: NICE [44,45].
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tional treatment of varices before 2013 should not be
neglected. Hence, we added another 48 cohorts (four
years) to the model and followed-up each of these co-
horts for five years (see Figure 1).
Patient cohorts and market shares of treatments for
varicose veins
German literature data exists only for the annual num-
ber of varicose vein surgeries performed in an inpatient
setting. Göckeritz estimates that surgeries still account
for about 90% of all interventional treatments for vari-
cose veins in Germany [17]. Under the assumptions that
the small number of patients treated with endovenous
thermal ablations within the SHI can be neglected (ex-
pert opinion) and all top-up treatments are UGFS (see
Table 1), about 95% of all interventional non-top-up
treatments have to be surgical and 5% sclerosing proce-
dures. Furthermore, about 60% of varicose vein surgeries
are undertaken in an outpatient setting according to ex-
perts’ estimates.
If ClosureFast is introduced in the SHI benefit cata-
logue, the market shares will shift – in particular at the
expense of surgery market shares. On the basis of expert
opinion, we assume that ClosureFast accounts for 10%
of all procedures in the year of its introduction and has
an annual market growth of five percentage points each
following year (Base Case assumption). The increase ofTable 2 Assumed market shares of interventional treatments
Market shares 2013
World without ClosureFast (1st and 2nd treatment)
Surgery 0.95
UGFS 0.05
World with ClosureFast (1st and 2nd treatment)
Surgery 0.85
ClosureFast 0.10
UGFS 0.05
* Excluding top-up treatment.the use of ClosureFast is assumed to reduce the market
share of surgeries equally. The medical experts do not
assume a reimbursement of EVLA by the SHI in the
near future; therefore, EVLA treatment was not included
in the budget impact analysis (Table 2).
In Germany, inpatient varicose vein surgeries are
coded as OPS 5–385 within the G-DRG system. Based
on the numbers of coded surgical procedures which
were derived from the German Federal Statistical Office
[47] as well as the above stated expert opinions on mar-
ket shares, we calculated the size of the monthly patient
cohorts. Table 3 shows the different steps of the calcula-
tion process in detail.
Effectiveness and adverse events
The effectiveness of the different treatment procedures
was modeled via recurrence data. “Success” of interven-
tional treatment was not considered in the model, as pa-
tients receive top-up treatments (additional treatment in
case of complications, i.e. vein has not been occluded or
obliterated) until the treatment episode is complete
[44,45] (NICE).
A recurrence describes varicose veins which occur in
the same area of the treated varice, independently of the
type of the initial treatment. Noppeney et al. distinguish
between three causes of recurrent varices: technical fail-
ure of the initial treatment, neovascularisation and pro-
gression of the venous disease [55]. About 20% offor varicose veins in Germany*
2014 2015 2016 2017
0.95 0.95 0.95 0.95
0.05 0.05 0.05 0.05
0.80 0.75 0.70 0.65
0.15 0.20 0.25 0.30
0.05 0.05 0.05 0.05
Table 3 Calculation of monthly patient cohorts
Annual inpatient
surgeries OPS
5-385*
Annual inpatient
surgeries of
SHI patients
Annual outpatient
surgeries of SHI
patients
Annual total
surgeries of SHI
patients
Annual total initial
surgeries of SHI
patients
Annual total initial
surgeries + UGFS
of SHI patients
Monthly total initial
surgeries + UGFS
of SHI patients
2009 147,445 125,328 187,992 313,321 250,657 263,849 21,987
2010 146,279 124,337 186,506 310,843 248,674 261,762 21,814
2011 146,351 124,398 186,598 310,996 248,797 261,891 21,824
2012-2017 146,0001 124,100 186,150 310,250 248,200 261,263 21,772
Calculation I II = I • 0.85 (85% of
patients in SHI)2
III = II • 1.5 (outpatient/
inpatient ratio)3
IV = II + III
(inpatient +
outpatient)
V = IV • 0.8 (initial procedures
account for 80% of total
procedures)4
VI = V • 1/0.95 (surgeries account for
95% of all non-top-up treatments)5
VII = VI • 1/12
1 Assumption.
2 German Federal Statistical Office [48].
3 Expert opinion.
4 [49-53].
5 Calculated based on Göckeritz [17], NICE [44] and expert opinion.
* The annual inpatient surgeries do not reflect the number of treated patients per year but the number of inpatient reimbursed procedures. The annual number of patients treated in an inpatient setting is lower [54].
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Differences in the initial treatment, the method of meas-
uring recurrences and duration of follow-up make a
comparison of recurrence rates difficult [56]. After surgi-
cal treatment of varicose veins and a follow-up period of
three to eleven years, recurrence rates of 26-62% have
been reported [57,58]. In addition, data indicates that
the rate of recurrences increases over time [59].
To gather data on recurrence rates as well as adverse
events of all relevant treatment options for varicose
veins, we performed a structured literature search in 44
databases using the database search tool of the German
Institute of Medical Documentation und Information
(DIMDI). Additionally, we conducted a hand research.
The search strategy targeted meta-analyses of RCTs for
surgery and UGFS as well as RCTs for ClosureFast.
The systematic literature review identified five meta-
analyses [32,44,60-62] which compared recurrence data as
well as adverse events of RFA and surgery. Two of these
studies [32,44] included a comparison between foam
sclerotherapy and surgery. Only one RCT was found
which reported recurrence rates as well as adverse events
of ClosureFast in comparison with surgery and UGFS
[18]. The study was also included in two of the identified
meta-analyses [44,62]. In total, six RCTs [18,36,63-66] pre-
senting relevant data on recurrence rates have been identi-
fied via the five meta-analyses. Table 7 of the Appendix
presents an overview of the reported recurrence rates.
Only Belcora et al. found a statistically significant differ-
ence in recurrences [63].
In the Base Case analysis, we used the effectiveness
data reported by NICE. Using a network meta-analysis
approach, the authors estimated a one-month recurrence
probability of 0.008331 for surgery, 0.005833 for
endovenous thermal ablations and 0.009141 for UGFS.
However, only a combined probability for RFA and
EVLA was calculated [44]. Since none of the other iden-
tified RCTs and meta-analyses found a statistically sig-
nificant difference between RFA and surgery, we made
the conservative assumption that ClosureFast had the
same effectiveness as surgery.
Adverse events were not included in the analysis. The
complications reported in different trials varied a lot and
different measurement methods were used. According to
a multidisciplinary Guideline Development Group,
which currently develops the NICE guidelines for the
diagnosis and management of varicose veins, adverse
event profiles of the different interventions are similar to
the extent that they can be neglected in health economic
models [44,45].
Resource use and cost data
Resource and cost data regarding the treatment of
varicose veins as well as the resulting side effects areonly available in the literature to a limited extent.
Therefore, we have identified relevant treatment pro-
cedures and resource usage via expert opinion and
official handbooks. Hence, we have evaluated the re-
source use from the perspective of the SHI in
Germany, taking also into consideration patient co-
payments as well as discounts for medications given
by the manufacturer and pharmacies as required by
legal obligations in Germany. For this, the current
German recommendations [67,68] for the valuation of
resource usage were applied to evaluate the costs from
the perspective of the SHI. In the Base Case analysis,
we assumed that costs of interventional treatments
in 2012 and costs of compression therapy in 2011
(no newer data currently available) would stay stable
over time. Considering the increasing costs of in-
patient treatment of varicose veins in recent years, this
is a conservative assumption, since rising prices of in-
patient procedures would have a greater effect on
overall surgery costs due to its higher inpatient ratio
compared with ClosureFast. However, price assump-
tions were varied in sensitivity analyses, e.g. by using
the mean annual price inflation rate of varice treat-
ments between 2005 and 2012, in order to take the
uncertainty regarding future price developments into
account. The historic development of surgery and
UGFS prices are shown in Table 8 of the Appendix.
In Germany, inpatient stays are reimbursed via lump
sums (diagnosis related groups, DRG). In these pay-
ments, in general all expenses of the hospital, incl. medi-
cation costs, are included. Relevant DRG were identified
via the German DRG-Catalogue [69] using the official
German DRG Definition Handbook from 2012 [70] and
evaluated from the perspective of the German SHI
[67-70].
Regarding the outpatient setting, we applied the offi-
cial German Uniform Valuation Scheme (EBM) [71] and
identified relevant OPS-codes for outpatient operations
for surgery as well as physician visits. Again, the above
mentioned recommendations for the evaluation were
used [67,68]. For general outpatient physician visits of
SHI-insured persons, it is important to mention that the
doctors are reimbursed via lump sum payments per
quarter, independent from the number of visits of an in-
dividual patient per quarter.
The proportion of patients treated in an outpatient
and inpatient setting, respectively, was identified via
expert opinion, since no official figures or litera-
ture data was available. Due to the uncertainty of
the proportions, extensive sensitivity analyses were
performed.
Table 4 summarizes the costs and effectiveness as well
as the setting of all interventional treatments for vari-
cose veins which were included in the BIA.
Table 4 Effectiveness, costs and setting of interventional treatments
Parameter Value Source
Interventional treatment effectiveness
Monthly probability of recurrence after 1st and 2nd treatment
Surgery 0.00833 NICE [44]
ClosureFast 0.00833 Assumption
UGFS 0.00914 NICE [44]
Probability of top-up treatment
Surgery 0.05 NICE [44]
ClosureFast 0.05 NICE[44]
UGFS 0.20 NICE [44]
Probability of receiving 2nd intervention after recurrence 0.75 NICE [44]
Treatment setting and costs
Outpatient treatment proportion
Surgery 0.60 Assumption
ClosureFast 0.90 Assumption
UGFS 1.00 Assumption
Inpatient treatment costs
Surgery 2,218.02 € DRG F39b
ClosureFast 2,218.02 € DRG F39b
Outpatient treatment costs
Surgery 639.45 € OPS-Code 5–385.70*
ClosureFast 1,100.00 € Assumption**
UGFS 47.23 €*** EBM-Codes 03111, 30501, 30500
Monthly costs of conservative compression therapy 11.45 € Kemper et al. [72]
* incl. operation and post-operative treatment.
** Average reimbursement in sub contracts between manufacturer and statutory health insurance funds.
*** EBM-Code 03111: 30.84 €, EBM-Code 30500: 16.30 €, EBM-Code 30501: 9.29 €.
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Various key inputs of the model are based on expert
opinions (e.g. outpatient ratio of treatments) or on lim-
ited evidence (e.g. recurrence rates of interventional
treatments for varicose veins) which may result in high
uncertainty of model outcomes. To test the robustness
of the model, we conducted three types of sensitivity
analyses. First, we performed one-way sensitivity ana-
lyses to assess the impact of variations in values of
every input parameter on the results. In order to test
how the results react to a simultaneous variation
of several inputs, we assumed four reasonable alternative
scenarios of which two scenarios (ClosureFast +
and ClosureFast++) were based on input values more
likely to favor a “World with ClosureFast” and two
other scenarios based on input values more likely to
favor a “World without ClosureFast” (ClosureFast- and
ClosureFast--). The alternative scenarios are summarized
and described in Table 9 of the Appendix. Furthermore,
we calculated the budget impact of the Base Case andthe 4 alternative scenarios for three different market
uptakes of ClosureFast:
 Base Case market uptake (10 percent points in the
year of introduction and 5 percent points in the
following years)
 Fast market uptake (15 percent points in the year of
introduction and 7,5 percent points in the following
years)
 Slow market uptake (5 percent points in the year of
introduction and 2,5 percent points in the following
years)
Finally, uncertainty was assessed using a probabilistic
sensitivity analysis (PSA). The PSA was carried out as a
Monte Carlo simulation with 10,000 iterations, simultan-
eously drawing random numbers for most model inputs
from the distributions listed in Table 10 of the Appendix.
The discount rate was set to 0% in all investigated sce-
narios (Base Case as well as sensitivity analyses), since
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no typical procedure in BIA [73].
Results
Base case
According to the results of the Base Case, the introduc-
tion of ClosureFast for the treatment of varicose veins
saves costs of about 19.1 Mio. € over a time period of
five years in Germany. Detailed results are shown in
Table 5. Since we assumed equal effectiveness between
ClosureFast and surgery, the inpatient and outpatient
treatment costs as well as the proportion of inpatient
procedures of ClosureFast and surgery, respectively, are
the factors which affected the results the most. While
the higher outpatient treatment costs of ClosureFast”
increases total costs on the one hand, the smaller pro-
portion of inpatient procedures reduces overall costs on
the other hand. All in all, the substitution of outpatient
for inpatient treatments overcompensate the higherTable 5 Results of the base case analysis
2013 2014
Total costs (cumulated)*
World without ClosureFast
402,442,098 € 402,227,395 €
(402,442,098 €) (804,669,493 €)
World with ClosureFast
400,534,663 € 399,367,497 €
(400,534,663 €) (799,902,160 €)
Difference
−1,907,435 € −2,859,898 €
(−1,907,435 €) (−4,767,333 €)
Inpatient costs (cumulated)
World without ClosureFast
274,282,077 € 274,162,435 €
(274,282,077 €) (548,444,512 €)
World with ClosureFast
252,637,930 € 241,709,792 €
(252,637,930 €) (494,347,722 €)
Difference
−21,644,147 € −32,452,643 €
(−21,644,147 €) (−54,096,790 €)
Outpatient costs (cumulated)**
World without ClosureFast
119,530,604 € 119,478,465 €
(119,530,604 €) (239,009,068 €)
World with ClosureFast
139,267,316 € 149,071,210 €
(139,267,316 €) (288,338,526 €)
Difference
19,736,712 € 29,592,745 €
(19,736,712 €) (49,329,458 €)
Inpatient costs/outpatient costs ratio (of cumulated costs)
World without ClosureFast
2.29 2.29
(2.29) (2.29)
World with ClosureFast
1.81 1.62
(1.81) (1.71)
* Including costs of conservative treatment.
** Excluding costs of conservative treatment.costs of ClosureFast in the outpatient setting. Over a
time horizon of five years, a total of 1,623,749 interven-
tional treatments for varicose veins are performed in
a “World without ClosureFast”. Of these, about 38% are
inpatient procedures causing about 70% of total inter-
ventional treatment costs. In a “World with ClosureFast”,
according to the results, about 32% of interventional treat-
ments for varicose veins are performed in an inpatient set-
ting causing about 60% of the total interventional
treatment costs.
One-way sensitivity analysis
Results of the one-way sensitivity analyses show that the
model outcome is highly sensitive to variations in inter-
ventional treatment prices (inpatient as well as out-
patient) and the proportion of outpatient treatments.
For instance, a 10% increase in the ClosureFast out-
patient price leads to additional costs of about 32 Mio €
in a “World with ClosureFast”. On the other hand, a2015 2016 2017
402,175,107 € 402,118,493 € 402,118,493 €
(1,206,844,600 €) (1,608,963,093 €) (2,011,081,587 €)
398,362,261 € 397,352,918 € 396,399,803 €
(1,198,264,421 €) (1,595,617,339 €) (1,992,017,142 €)
−3,812,846 € −4,765,575 € −5,718,690 €
(−8,580,179 €) (−13,345,754 €) (−19,064,445 €)
274,137,354 € 274,109,746 € 274,109,746 €
(822,581,865 €) (1,096,691,611 €) (1,370,801,358 €)
230,870,333 € 220,030,426 € 209,213,366 €
(725,218,054 €) (945,248,480 €) (1,154,461,846 €)
−43,267,021 € −54,079,320 € −64,896,380 €
(−97,363,811 €) (−151,443,131 €) (−216,339,512 €)
119,467,534 € 119,455,503 € 119,455,503 €
(358,476,603 €) (477,932,106 €) (597,387,609 €)
158,921,709 € 168,769,248 € 178,633,193 €
(447,260,235 €) (616,029,483 €) (794,662,676 €)
39,454,175 € 49,313,744.85 € 59,177,690 €
(88,783,632 €) (138,097,377 €) (197,275,067 €)
2.29 2.29 2.29
(2.29) (2.29) (2.29)
1.45 1.30 1.17
(1.62) (1.53) (1.45)
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ment results in additional savings of the same amount.
Variations in the values of other input parameters
(monthly probability of recurrence, probability of requir-
ing top-up treatment and probability of receiving a 2nd
interventional treatment) only had minor effects on the
model outcome. Results of all performed one-way sensi-
tivity analyses are shown in Table 11 of the Appendix.Scenario analyses
The results of the scenario analyses are presented in Table 6.
As one might expect, the introduction of ClosureFast saves
more costs in the scenarios with input values favoring
a “World with ClosureFast” compared with the Base
Case. However, in the two other scenarios (ClosureFast-,
ClosureFast–), the introduction of ClosureFast is not cost
saving anymore and causes up to 300 Mio € of add-
itional costs for the SHI in five years. A variation of the
market uptake does not change the results qualitatively;
solely the total costs as well as the cost difference vary
between a “World with ClosureFast” and a “World
without ClosureFast”.Probabilistic sensitivity analysis (PSA)
According to the results of the PSA, illustrated in
Figure 2, a “World with ClosureFast” saves costs with a
probability of about 59% over a time horizon of five
years. With a probability of 25% cost savings of over 75
Mio € can be realized in a “World with ClosureFast”.
However, with the same probability (25%) the introduc-
tion of ClosureFast is likely to cause additional costs of
at least 37 Mio € in the SHI. All in all, it has to be noted
that there is high uncertainty regarding the results,
which reflects the limited evidence of several key input
parameters.Table 6 Results of the scenario analyses after 5 years
Base case ClosureFas
Base Case market uptake of ClosureFast (10 percent points in the year
World without ClosureFast 2,011,081,587 € 2,116,615,576
World with ClosureFast 1,992,017,142 € 2,039,393,961
Difference −19,064,445 € −77,221,615
Fast market uptake of ClosureFast (15 percent points in the year of int
World without ClosureFast 2,011,081,587 € 2,116,615,576
World with ClosureFast 1,982,484,920 € 2,001,065,612
Difference −28,596,667 € −115,549,964
Slow market uptake of ClosureFast (5 percent points in the year of intr
World without ClosureFast 2,011,081,587 € 2,116,615,576
World with ClosureFast 2,001,549,364 € 2,077,910,616
Difference −9,532,223 € −38,704,960Discussion
This study is the first to analyze the budget impact of
different treatment scenarios for patients with varicose
veins in the German setting. According to the results,
ClosureFast has the potential to be cost saving for the
German SHI.
Our model calculated about 308,000 surgeries of vari-
cose veins in the SHI per year. These figures are based
on a combination of the annual number of varicose vein
surgeries performed in an inpatient setting and expert
opinion. Nüllen et al. estimated that over 350,000 sur-
gery treatments for varices are performed every year in
Germany, including private insured patients [74]. Since
about 85% of the German population is covered by the
SHI [48], the model calculation is in line with the esti-
mation of Nüllen et al. Furthermore, based on the recur-
rence rates used in the Base Case, our model calculated
248,200 initial surgery procedures which accounts for a
proportion of 80.5 percent of all surgery procedures.
These results agree with findings in the literature that
recurrence treatments account for about 20% [49-53] of
all surgery treatments for varicose veins.
In the Base Case scenario, ClosureFast is dominant com-
pared to surgery, since it is cost-saving while being equally
effective. This is a conservative estimation, since other stud-
ies report a higher effectiveness of ClosureFast [33]. Our
findings are supported by the results of the NICE model
which also reported dominance of ClosureFast [44]. To our
knowledge, there is only one other BIA [75] (for the
Ontario setting) which analyses the budget impact of
radiofrequency ablation. In contrast to our Base Case ana-
lysis, the authors conclude that the introduction of
radiofrequency ablation leads to additional costs [75]. A
cost-effectiveness study, conducted by Gohel et al., esti-
mated less costs for RFA compared to stripping but also in-
ferior outcomes [76]. In contrast to our analysis, Gohelt+ ClosureFast++ ClosureFast- ClosureFast–
of introduction and 5 percent points in the following years)
€ 2,431,191,408 € 1,938,122,196 € 1,588,229,622 €
€ 2,244,025,455 € 1,996,246,708 € 1,829,572,902 €
€ −187,165,953 € 58,124,512 € 241,343,280 €
roduction and 7.5 percent points in the following years)
€ 2,431,191,408 € 1,938,122,196 € 1,588,229,622 €
€ 2,152,055,284 € 2,025,308,963 € 1,913,810,466 €
€ −279,136,124 € 87,186,767 € 325,580,844 €
oduction and 2.5 percent points in the following years)
€ 2,431,191,408 € 1,938,122,196 € 1,588,229,622 €
€ 2,337,070,830 € 1,967,184,452 € 1,743,326,614 €
€ −94,120,578 € 29,062,256 € 155,096,992 €
Figure 2 Results of the probabilistic sensitivity analysis.
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and only took recurrences over a time horizon of three
month into account [76].
The evaluation was conducted from the perspective
of the SHI in Germany. Hence, indirect costs of work
loss were not included in the analysis. Considering
the shorter time to resume work after RFA treatment
compared with surgery [18,32,62], cost savings of intro-
ducing ClosureFast into the general benefit catalogue
of the SHI should be even higher from a social
perspective.
This study has some limitations, especially due to a
lack of solid data in the literature. The lack of evidence
of several key input parameters (in particular expert
opinion for the treatment setting) resulted in high un-
certainty regarding the outcomes of the model. In
addition, there is only limited evidence regarding the ef-
fectiveness of treatments for varicose veins in preventing
recurrences in the short term and particularly in the
long term. Randomized RCTs with high number of pa-
tients are missing. Due to the insufficient power, the
RCTs [18,36,64,65], which were conducted in this indi-
cation could not show any statistical differences in re-
currence rates between different RFA and surgery.
Therefore, there is urgent need of high quality RCTs.
In general, due to the specialty of the reimbursement
system in Germany, the results of this model are not dir-
ectly transferable to foreign settings. Furthermore, as
described earlier, the treatment strategies differ fromforeign settings. For instance, surgery is still the domin-
ant treatment strategy in Germany and EVLA plays no
role. However, the model structure allows for incorpor-
ating EVLA into the analysis and can be adapted to
other settings.
Conclusions
The analysis suggests that the introduction of ClosureFast
for patients with varicose veins is cost-saving compared to
the status quo in the German SHI setting. Even though
the procedure ClosureFast is more expensive in an out-
patient setting, cost savings occur due to a substitution of
outpatient for inpatient treatments. However, the results
scatter in the sensitivity analyses due to limited evidence
of some key input parameters.
Ethical approval for research
Ethical approval is not needed for budget impact analyses.
Appendix
The files in the appendix provide additional information
on reported recurrence rates of varicose veins after inter-
ventional treatment (Table 7), the development of SHI
prices of interventional treatments for varicose veins
(Table 8), a detailed summary and description of all rele-
vant input parameters for the scenario (Table 9) and the
probabilistic sensitivity analysis (Table 10) as well as the
results of the one-way sensitivity analyses (Table 11).
Table 7 Recurrence rates of relevant treatment options reported in RCTs
Author Year Length of follow-up in months (number of patients at last follow up) Number of patients (limbs) Recurrence rate
ClosureFast vs. Surgery vs. UGFS
Rasmussen [18] 2011 12 (ClosureFast: 106 Surgery: 97 UGFS: 107) ClosureFast: 125 (148) ClosureFast: 9/124 = 7.26%
Surgery: 125 (143) Surgery: 16/108 = 14.81%
UGFS: 125 (145) UGFS: 17/123 = 13.82%
Odds ratio (ClosureFastvs Surgery): 0.45
Odds ratio (ClosureFastvs UGFS): 0.49
Odds ratio (UGFS vs Surgery): 0.92
ClosurePlus vs. Surgery
Perälä [36] 2005 36 (ClosurePlus: 15 Surgery: 13) ClosurePlus: 15 (15) ClosurePlus: 5/15 = 33.33%
Surgery: 13 (13) Surgery: 3/13 = 23.1%
Odds ratio: 1.67
Lurie [64] 2005 24 (ClosurePlus: 36 Surgery: 29) ClosurePlus: 43 (44) ClosurePlus: 5/36 = 13.89%
Surgery: 36 (36) Surgery: 6/29 = 20.69%
Odds ratio: 0.62
Helmy Elkaffes [65] 2011 24 (ClosurePlus: 81 Surgery: 81) ClosurePlus: 90 (90) ClosurePlus: 12/81 = 14.81%
Surgery: 90 (90) Surgery: 9/81 = 11.11%
Odds ratio: 1.39
UGFS vs. Surgery
Shadid [66] 2012 24 (UGFS: 213 Surgery: 177) UGFS: 230 (230) UGFS: 24/213 = 11.27%
Surgery: 200 (200) Surgery: 16/177 = 9.04%
Odds ratio: 1.28
Foam Sclerotherapy vs Surgery
Belcaro [63] 2000 120 Foam Sclerotherapy: 148 Foam Sclerotherapy: 56/148 = 37.84%
Surgery: 155 Surgery: 38/155 = 24,52%
Surgery: 200 (200) Odds Ratio: 1.87
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Table 8 Development of SHI prices of interventional treatments for varicose veins
Surgery UGFS
(outpatient
only)**Inpatient* Outpatient**
2004 1,811.71 € n/s n/s
2005 1,726.92 € n/s n/s
2006 1,745.41 € n/s n/s
2007 1,821.26 € n/s n/s
2008 1,861.95 € n/s n/s
2009 2,039.82 € 638.59 € 56.35 €
2010 2,066.19 € 639.45 € 56.43 €
2011 2,074.22 € 639.45 € 56.43 €
2012 2,218.02 € 639.45 € 56.43 €
2013 n/s 645.20 € 56.93 €
* InEK GmbH – Institute for the Hospital Remuneration System: Diagnosis Related Group-Catalogue 204–2012. Düsseldorf: Dt. Krankenhaus-Verl.-Ges.; 2003–2011.
** National Association of Statutory Health Insurance Physicians: Uniform Value Scale 2009–2012. http://www.kbv.de.
Table 9 Input parameters modified in the scenario analyses#
Parameter Base case ClosureFast+ ClosureFast++ ClosureFast- ClosureFast–
Monthly probability of recurrence after 1st and 2nd treatment
Surgery 0.00833 0.00833 0.01326** 0.00833 0.00490***
ClosureFast 0.00833 0.00583* 0.00630** 0.00833 0.00666***
UGFS 0.00914 0.00914 0.00914 0.00914 0.00914
* Monthly recurrence rate of endovenous thermal ablation reported by NICE [45]; ** monthly recurrence rate based on Rasmussen et al. [18]; ***
monthly recurrence rates based on Helmy Elkaffas et al. [65]
Surgery outpatient treatment ratio
2013 0.600 0.600 0.600 0.600 0.660**
2014 0.600 0.600 0.600 0.615* 0.690**
2015 0.600 0.600 0.600 0.630* 0.720**
2016 0.600 0.600 0.600 0.645* 0.750**
2017 0.600 0.600 0.600 0.660* 0.780**
* outpatient treatment ratio increases by 1.5 percent points per year; ** outpatient treatment ratio 6 percent points higher in 2013 and increases by 3
percent points per year
Surgery inpatient costs
2013 2,218.02 € 2,270.54 €* 2.323,06 €** 2,218.02 € 2,218.02 €
2014 2,218.02 € 2,324.30 €* 2.433,07 €** 2,218.02 € 2,218.02 €
2015 2,218.02 € 2,379.34 €* 2.548,30 €** 2,218.02 € 2,218.02 €
2016 2,218.02 € 2,435.68 €* 2.668,98 €** 2,218.02 € 2,218.02 €
2017 2,218.02 € 2,439.35 €* 2.795,37 €** 2,218.02 € 2,218.02 €
* mean annual price inflation rate 2004–2012 (2.37%); ** mean annual price inflation rate 2004–2012 times two
Surgery inpatient treatment costs
2013 639.45 € 645.20 €* 645.20* € 639.45 € 639.45 €
2014 639.45 € 645.20 €* 645.20* € 639.45 € 639.45 €
2015 639.45 € 645.20 €* 645.20* € 639.45 € 639.45 €
2016 639.45 € 645.20 €* 645.20* € 639.45 € 639.45 €
2017 639.45 € 645.20 €* 645.20* € 639.45 € 639.45 €
* price based on new EBM point value (0.035363 € per point)
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Table 9 Input parameters modified in the scenario analyses# (Continued)
ClosureFast outpatient treatment ratio
2013 0.90 0.90 0.95 0.90 0.85*
2014 0.90 0.90 0.95 0.90 0.85*
2015 0.90 0.90 0.95 0.90 0.85*
2016 0.90 0.90 0.95 0.90 0.85*
2017 0.90 0.90 0.95 0.90 0.85*
* outpatient treatment ration 5 percent points lower than estimated by experts
ClosureFastinpatient costs
2013 2,218.02 € 2,270.54 €* 2,023.06 €** 2,218.02 € 2,218.02 €
2014 2,218.02 € 2,324.30 €* 2,118.87 €** 2,218.02 € 2,218.02 €
2015 2,218.02 € 2,379.34 €* 2,219.21 €** 2,218.02 € 2,218.02 €
2016 2,218.02 € 2,435.68 €* 2,324.31 €** 2,218.02 € 2,218.02 €
2017 2,218.02 € 2,493.35 €* 2,434.38 €** 2,218.02 € 2,218.02 €
* mean annual price inflation rate 2004–2012 (2,37%); ** mean annual price inflation rate 2004–2012 times two + inpatient costs of ClosureFast 300 €
lower than surgery inpatient costs in 2013
ClosureFast inpatient costs
2013 1,100.00 € 1,000.00 € 900.00 € 1,300.00 € 1,500.00 €
2014 1,100.00 € 1,000.00 € 900.00 € 1,300.00 € 1,500.00 €
2015 1,100.00 € 1,000.00 € 900.00 € 1,300.00 € 1,500.00 €
2016 1,100.00 € 1,000.00 € 900.00 € 1,300.00 € 1,500.00 €
2017 1,100.00 € 1,000.00 € 900.00 € 1,300.00 € 1,500.00 €
Market shares
2013-2017 Base Case Base Case Base Case Base Case *
Volume increase of the market
2013-2017 Base Case Base Case Base Case Base Case **
# BaseCase values were maintained for all other input parameters.
* Base Case; but ClosureFast takes 2.5 percent points of UGFS market shares in the first year.
** Due to the introduction of ClosureFast the volume of the market increases by 0.5 percent points every year.
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Table 10 Means, standard errors and distributions of input parameters varied in the probabilistic sensitivity analysis
Mean Standard error Distribution
Initial intervention population
2013-2017 261,263 2,500 normal
Monthly survival probability
0.99944 0.0001 normal
Monthly probability of recurrence after initial and 2nd interventional treatment
Surgery 0.008331 0.00164 beta
ClosureFast 0.008331 0.00176 beta
UGFS 0.009141 0.00105 beta
Probability of requiring top-up treatment after initial and 2nd interventional treatment
Surgery 0.05000 0.00021 uniform
ClosureFast 0.05000 0.00021 uniform
UGFS 0.20000 0.00333 uniform
Probability of receiving 2nd interventional treatment
0.75000 0.02083 uniform
Weighted mean of in- and outpatient interventional treatment costs (per procedure)
Surgery 1,270.88 € 190.63 € gamma
ClosureFast 1,211.80 € 181.77 € gamma
UGFS 56.43 € 8.46 € gamma
Monthly costs of compression therapy
11.45 € 1.14 € gamma
ClosureFast market uptake (in percent points)
2013 0.10000 0.00083 uniform
2014-2017 0.05000 0.00021 uniform
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Table 11 Results of one-way sensitivity analysis
Input values Results (Difference: “World with ClosureFast” - World without ClosureFast”)
Base case + 10% - 10% Base case + 10% - 10%
Monthly probability of recurrence after initial and 2nd interventional treatment
Surgery 0.00833 0.00916 0.00750 −19,064,444 € −22,282,157 € −15,786,834 €
ClosureFast 0.00833 0.00916 0.00750 −19,064,444 € −16,130,411 € −22,067,845 €
UGFS 0.00914 0.01006 0.00823 −19,064,444 € −19,079,598 € −19,048,601 €
Probability of requiring top-up treatment after initial and 2nd interventional treatment
Surgery 0.05000 0.05500 0.04500 −19,064,444 € −19,155,492 € −18,973,397 €
ClosureFast 0.05000 0.05500 0.04500 −19,064,444 € −18,973,397 € −19,155,492 €
UGFS 0.20000 0.22000 0.18000 −19,064,444 € −19,064,444 € −19,064,444 €
Probability of receiving 2nd interventional treatment
0.75000 0.82500 0.67500 −19,064,444 € −19,427,439 € −18,701,450 €
Inpatient costs of interventional treatment (per procedure)
Surgery 2,218.02 € 2,439.82 € 1,996.22 € −19,064,444 € −47,695,356 € 9,566,467 €
ClosureFast 2,218.02 € 2,439.82 € 1,996.22 € −19,064,444 € −11,906,717 € −26,222,172 €
Outpatient costs of interventional treatment (per procedure)
Surgery 639.45 € 703.40 € 575.51 € −19,064,444 € −31,445,797 € −6,683,092 €
ClosureFast 1,100.00 € 1,210.00 € 990.00 € −19,064,444 € 12,883,647 € −51,012,536 €
UGFS 56.43 € 62.07 € 50.78 € −19,064,444 € −19,064,444 € −19,064,444 €
Proportion of outpatient treatments
Surgery 0.60000 0.66000 0.54000 −19,064,444 € 11,500,570 € −49,629,459 €
ClosureFast 0.90000 0.99000 0.81000 −19,064,444 € −51,535,903 € 13,407,014 €
Monthly costs of compression therapy
11.45 € 12.59 € 10.30 € −19,064,444 € −19,064,444 € −19,064,444 €
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